How to Get Trulicity in Arizona: Telehealth, Prescriptions, and Pharmacy Access

What Is Trulicity and Why Arizona Patients Seek It

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection for adults with type 2 diabetes. The FDA approved it in September 2014 for glycemic control and later recognized its cardiovascular benefit following the REWIND cardiovascular outcomes trial [1][2].

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 showed that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE) by 12% compared with placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P<0.05) in patients with type 2 diabetes who had existing cardiovascular disease or multiple risk factors [1]. That finding drove prescriber interest well beyond endocrinology into primary care and internal medicine.

Arizona has one of the fastest-growing rates of type 2 diabetes in the southwestern United States. The CDC's 2023 National Diabetes Statistics Report estimates that 11.6% of U.S. adults have diagnosed diabetes, with Arizona rates tracking above the national average in several counties [3]. Demand for GLP-1 receptor agonists in the state has risen accordingly, pushing patients toward telehealth platforms when in-person wait times stretch to months.

Trulicity is available only by prescription under federal law [2]. No Arizona exemption exists. Every pathway to the drug, whether in-person or online, begins with a licensed prescriber.

Who Can Prescribe Trulicity in Arizona

Any Arizona-licensed prescriber with Schedule III-V authority can write a dulaglutide prescription. Practically, that covers MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Arizona is a full-practice-authority state for nurse practitioners under A.R.S. § 32-1606, meaning NPs do not require physician supervision to prescribe [4]. PAs in Arizona practice under a supervising or collaborating physician arrangement per A.R.S. § 32-2536, but they hold independent prescribing authority for non-controlled substances including dulaglutide [5]. Telehealth platforms operating in Arizona frequently staff NPs and PAs for GLP-1 consultations precisely because of this legal structure.

Prescribers must hold an active Arizona license. A clinician licensed only in California or Texas cannot legally prescribe to an Arizona patient unless they also hold Arizona licensure or use the Interstate Medical Licensure Compact (IMLC), which Arizona joined in 2015 [6]. Patients using national telehealth platforms should confirm the assigned clinician holds an active Arizona license before the visit concludes.

The Arizona Medical Board and Arizona State Board of Nursing both publish real-time license verification tools online [4][5]. Spending 90 seconds on that lookup before committing to a telehealth subscription is worthwhile.

How Arizona Telehealth Prescribing Works for Trulicity

Arizona law permits synchronous audio-video telehealth as a valid encounter for establishing a new patient relationship and writing a new prescription, including GLP-1 receptor agonists [7]. The Arizona Revised Statutes § 36-3601 through § 36-3606 govern telehealth practice standards, requiring the same standard of care as an in-person visit [7].

A typical telehealth visit for Trulicity proceeds like this. The patient completes an intake form disclosing current medications, prior diagnoses, and family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), both absolute contraindications listed in the FDA label [2]. The clinician reviews recent labs or orders them through a partnered lab draw service. A synchronous video call follows, usually 15 to 30 minutes, during which the clinician confirms the type 2 diabetes diagnosis, discusses injection technique, and addresses contraindications. The prescription is sent electronically to a pharmacy of the patient's choice.

Asynchronous-only (store-and-forward) models are legal in Arizona for some services but are generally insufficient for a first-time controlled or REMS-adjacent prescription. Reputable GLP-1 telehealth platforms use synchronous video for the initial visit [7]. Follow-up visits at 4 weeks, 12 weeks, and quarterly thereafter may be asynchronous in some practice models.

HealthRX clinicians follow the American Diabetes Association (ADA) 2024 Standards of Care, which recommend GLP-1 receptor agonists as a preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease [8]. The ADA guideline states directly: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" [8].

Labs Required Before Starting Trulicity in Arizona

Baseline laboratory work is not optional. Responsible prescribers, whether in-person or via telehealth, will require recent labs before finalizing a dulaglutide prescription.

The standard panel includes: hemoglobin A1c (HbA1c) to confirm the type 2 diabetes diagnosis and establish a glycemic baseline; a comprehensive metabolic panel (CMP) to assess renal function and hepatic enzymes; a fasting lipid panel; and a urinalysis with urine albumin-to-creatinine ratio (UACR) if kidney disease is suspected [8][9]. Thyroid function testing is not mandated by the FDA label but is often ordered at baseline given the MTC risk signal observed in rodent studies [2].

Most Arizona telehealth platforms partner with LabCorp, Quest Diagnostics, or Sonora Quest (a regional Arizona lab network) for in-person blood draws. Results are typically returned within 24 to 72 hours. Some platforms accept labs drawn within the prior 6 months if the patient can upload documentation.

The FDA label for Trulicity specifies that the drug is contraindicated in patients with a personal or family history of MTC or MEN 2, and in patients with a prior serious hypersensitivity reaction to dulaglutide [2]. Pancreatitis history warrants careful risk-benefit discussion. Patients with an eGFR <15 mL/min/1.73 m² (severe renal impairment) should use dulaglutide with caution; no dose adjustment is required by the label, but clinical monitoring is recommended [2].

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of type 2 diabetes supports HbA1c and renal function as the minimum pre-prescribing workup for any GLP-1 receptor agonist [9].

Prior Authorization in Arizona: What to Expect

Prior authorization (PA) is the single biggest delay in getting Trulicity. Most Arizona commercial insurance plans require it, and the process can take 3 to 14 business days.

The standard documentation packet for a Trulicity PA in Arizona typically includes: a letter of medical necessity from the prescriber; current HbA1c (usually requiring a value above 7.0% or 7.5% depending on the plan); documentation of at least one prior oral antidiabetic agent (most commonly metformin) tried and either failed or contraindicated; the patient's current diabetes medication list; and, for cardiovascular benefit claims, documentation of established ASCVD or high cardiovascular risk [10].

Arizona's AHCCCS (Medicaid) program does not cover Trulicity as a preferred drug as of 2025. Patients covered by AHCCCS may have access to other GLP-1 agents on the AHCCCS preferred drug list, but dulaglutide is not among them [11]. AHCCCS beneficiaries seeking dulaglutide will need to pursue a non-preferred drug exception, which requires additional clinical justification and is frequently denied at the first submission.

Medicare Part D plans in Arizona vary. Some cover dulaglutide in Tier 3 or Tier 4 with a PA requirement. The Lilly Insulin Value Program and Lilly's Trulicity savings card can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month, though these programs are not available for government-insured patients [12].

Telehealth platforms with dedicated prior authorization teams can accelerate the process by submitting complete documentation on the same day as the clinical visit. Patients should ask any platform whether PA support is included in the service fee before signing up.

Arizona Pharmacy Options for Filling Trulicity

Brand-name Trulicity is stocked by most major retail pharmacy chains operating in Arizona, including CVS, Walgreens, Fry's Pharmacy (Kroger), Walmart Pharmacy, and Safeway Pharmacy. Specialty pharmacy fulfillment through Optum Rx, Accredo, or Express Scripts is common when a PA routes through a pharmacy benefits manager.

Without insurance, the list price of Trulicity runs approximately $900 to $1,000 per monthly supply (four single-dose pens) as of mid-2025. GoodRx and similar discount programs can reduce that to $650 to $800 at some Arizona locations, though prices fluctuate by zip code and pharmacy contract.

Mail-order pharmacy is legal and common in Arizona. A 90-day supply through a mail-order pharmacy connected to a commercial plan typically carries a lower copay than 30-day retail fills. Arizona law permits licensed out-of-state pharmacies to mail medications to Arizona residents provided the pharmacy holds an Arizona Board of Pharmacy nonresident pharmacy permit [13].

The Arizona State Board of Pharmacy maintains a public database of licensed pharmacies, including out-of-state mail-order facilities [13]. Patients should verify the dispensing pharmacy's license before supplying payment information to any online pharmacy.

503A Compounding Pharmacies and Dulaglutide in Arizona

Arizona-licensed 503A compounding pharmacies are permitted to prepare compounded dulaglutide for individual patients based on a valid patient-specific prescription from a licensed prescriber. This option has grown in relevance as brand-name Trulicity supply has tightened and cost barriers remain high for uninsured patients.

503A pharmacies operate under state board of pharmacy oversight and must compound for an identified individual patient, not in anticipation of prescriptions [14]. Compounded dulaglutide is not FDA-approved and is not bioequivalent-tested against the brand product. The FDA has stated that compounded versions of GLP-1 receptor agonists prepared by 503A pharmacies exist in a separate regulatory framework from FDA-approved drugs [14].

The FDA issued guidance in 2024 clarifying that once an approved drug is removed from the drug shortage list, 503A compounders lose the explicit shortage-based justification for preparing that compound [14]. Patients and prescribers should confirm current shortage status and pharmacy compliance at the time of prescribing. The HealthRX medical team reviews 503A pharmacy partners quarterly for licensure and quality documentation.

A 2022 analysis in JAMA Internal Medicine found significant variability in compounded GLP-1 product quality across unregulated online pharmacies, underscoring the importance of using only Arizona Board of Pharmacy-verified facilities [15].

How Long Until You Receive Trulicity in Arizona

The timeline from initial consultation to first injection depends on three variables: lab completion, prior authorization duration, and pharmacy fulfillment speed.

Best-case scenario: labs already on file, no insurance PA required, and a cash-pay prescription sent to a local retail pharmacy. In that situation, a patient could inject the first dose within 24 to 48 hours of the telehealth visit.

Typical scenario with insurance: 3 to 10 business days for PA approval, plus 1 to 3 days for pharmacy fulfillment. Total time from visit to first dose is usually 7 to 14 days. Mail-order adds 3 to 7 shipping days on top of the PA wait.

PA denial adds time. First-level appeals in Arizona commercial insurance plans must be acknowledged within 72 hours for urgent requests and 30 days for standard requests under Arizona insurance code [10]. Expedited PA requests, submitted when the prescriber documents clinical urgency, are adjudicated within 72 hours under most Arizona plan contracts.

Patients who cannot afford brand-name Trulicity while awaiting PA approval should ask their prescriber about Lilly's free trial program, which provides up to two free starter pens for eligible commercially insured patients [12].

Transferring a Trulicity Prescription to Arizona

Patients relocating to Arizona from another state can transfer an existing Trulicity prescription to an Arizona pharmacy, provided the prescription was written by a licensed prescriber and has refills remaining. Federal law under the Uniform Controlled Substances Act does not restrict transfer of non-scheduled prescriptions across state lines [16]. Dulaglutide is not a scheduled substance.

The receiving Arizona pharmacy will contact the out-of-state pharmacy to confirm the prescription details. Electronic prescriptions (e-prescriptions) can be transferred electronically between pharmacies on compatible systems; paper prescriptions require the original to be physically presented at the new pharmacy in most cases.

One practical complication: if a prior authorization was granted by an out-of-state insurer, the Arizona plan may require a new PA even for a transferred prescription. Patients should contact their Arizona insurance plan's pharmacy benefits line before assuming coverage will continue seamlessly.

Patients moving to Arizona should also establish care with an Arizona-licensed prescriber within 90 days to ensure uninterrupted access to refills. A telehealth visit with an Arizona-licensed clinician satisfies this requirement and avoids a gap in medication supply [7].

Dosing and Administration: Clinical Basics

Trulicity is initiated at 0.75 mg once weekly by subcutaneous injection into the abdomen, thigh, or upper arm [2]. After 4 weeks, the dose is increased to 1.5 mg once weekly, which is the minimum effective dose for most patients. The FDA label permits further titration to 3.0 mg and then 4.5 mg once weekly for additional glycemic control, with each dose increase occurring after at least 4 weeks at the current dose [2].

The injection is administered using a single-dose auto-injector pen. Each pen contains one dose. Used pens are sharps waste and must be disposed of in an FDA-cleared sharps container, not in household trash. Arizona's Sharps Management Program provides disposal guidelines and authorized collection sites [17].

Gastrointestinal adverse effects, including nausea, vomiting, and diarrhea, are the most common reason patients discontinue dulaglutide. In the AWARD-5 trial (N=1,098), nausea occurred in 21.3% of patients receiving dulaglutide 1.5 mg versus 5.3% of placebo patients, with most events resolving within 2 to 4 weeks of treatment initiation [18]. Slow titration and taking the injection with a small meal may reduce early GI side effects.

The ADA 2024 Standards of Care note that GLP-1 receptor agonists produce moderate weight reduction as a secondary effect in patients with type 2 diabetes, with dulaglutide 1.5 mg associated with approximately 3 kg mean weight loss at 26 weeks in controlled trials [8]. Patients seeking primary weight management should discuss semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), which have demonstrated larger weight-loss effects in their respective outcome trials [19].